1 November 2024 - The November 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The November issue of the Schedule includes several new/revised listings of note:

• Mechlorethamine hydrochloride (Ledaga) - new medicine
• Risdiplam (Evenity) - new indication
• Romosozumab (Evenity) - new indication
• Sitagliptin phosphate monohydrate with dapagliflozin propanediol monohydrate (Sidapvia) - new combination product

Read Summary of PBS changes